Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest - PubMed (original) (raw)
Clinical Trial
. 2007 May 1;25(13):1670-6.
doi: 10.1200/JCO.2006.09.0928.
Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, Gianluca Masi; Gruppo Oncologico Nord Ovest
Affiliations
- PMID: 17470860
- DOI: 10.1200/JCO.2006.09.0928
Clinical Trial
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest
Alfredo Falcone et al. J Clin Oncol. 2007.
Abstract
Purpose: The Gruppo Oncologico Nord Ovest (GONO) conducted a phase III study comparing fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI [irinotecan 165 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, leucovorin 200 mg/m2 day 1, fluorouracil 3,200 mg/m2 48-hour continuous infusion starting on day 1, every 2 weeks]) with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI).
Methods: Selection criteria included unresectable metastatic colorectal cancer, age 18 to 75 years, and no prior chemotherapy for advanced disease. The primary end point was response rate (RR).
Results: A total of 244 patients were randomly assigned. An increase of grade 2 to 3 peripheral neurotoxicity (0% v 19%; P < .001), and grade 3 to 4 neutropenia (28% v 50%; P < .001) were observed in the FOLFOXIRI arm. The incidence of febrile neutropenia (3% v 5%) and grade 3 to 4 diarrhea (12% v 20%) were not significantly different. Responses, as assessed by investigators, were, for FOLFIRI and FOLFOXIRI, respectively, complete, 6% and 8%; and partial, 35% and 58%, (RR, 41% v 66%; P = .0002). RR confirmed by an external panel was 34% versus 60% (P < .0001). The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = .033, among all 244 patients; and 12% v 36%; P = .017 among patients with liver metastases only). Progression-free survival (PFS) and overall survival (OS) were both significantly improved in the FOLFOXIRI arm (median PFS, 6.9 v 9.8 months; hazard ratio [HR], 0.63; P = .0006; median OS, 16.7 v 22.6 months; HR, 0.70; P = .032).
Conclusion: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics. Further studies of FOLFOXIRI in combination with targeted agents and in the neoadjuvant setting are warranted.
Similar articles
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Masi G, et al. Lancet Oncol. 2010 Sep;11(9):845-52. doi: 10.1016/S1470-2045(10)70175-3. Epub 2010 Aug 9. Lancet Oncol. 2010. PMID: 20702138 Clinical Trial. - Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A. Fornaro L, et al. Clin Colorectal Cancer. 2012 Mar;11(1):71-6. doi: 10.1016/j.clcc.2011.06.013. Epub 2011 Sep 8. Clin Colorectal Cancer. 2012. PMID: 21903485 - Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Clinical Trial. - Chemotherapy of metastatic colorectal cancer.
[No authors listed] [No authors listed] Prescrire Int. 2010 Oct;19(109):219-24. Prescrire Int. 2010. PMID: 21180382 Review. - Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
Masi G, Vasile E, Loupakis F, Bursi S, Ricci S, Petrini I, Fontana A, Allegrini G, Falcone A. Masi G, et al. Clin Colorectal Cancer. 2008 Jan;7(1):7-14. doi: 10.3816/CCC.2008.n.002. Clin Colorectal Cancer. 2008. PMID: 18279572 Review.
Cited by
- Comparison of systemic treatments for previously treated patients with unresectable colorectal liver metastases: a systematic review and network meta-analysis.
Jiang Y, Zhao M, Tang W, Zheng X. Jiang Y, et al. Front Oncol. 2024 Jul 10;14:1293598. doi: 10.3389/fonc.2024.1293598. eCollection 2024. Front Oncol. 2024. PMID: 39050571 Free PMC article. - Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y. Nakatsumi H, et al. Front Oncol. 2022 Nov 9;12:939425. doi: 10.3389/fonc.2022.939425. eCollection 2022. Front Oncol. 2022. PMID: 36439491 Free PMC article. - Colorectal cancer biomarkers and the potential role of cancer stem cells.
Langan RC, Mullinax JE, Raiji MT, Upham T, Summers T, Stojadinovic A, Avital I. Langan RC, et al. J Cancer. 2013;4(3):241-50. doi: 10.7150/jca.5832. Epub 2013 Mar 15. J Cancer. 2013. PMID: 23459666 Free PMC article. - Colorectal cancer.
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T. Kuipers EJ, et al. Nat Rev Dis Primers. 2015 Nov 5;1:15065. doi: 10.1038/nrdp.2015.65. Nat Rev Dis Primers. 2015. PMID: 27189416 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical